Brokerages Anticipate Genocea Biosciences Inc (GNCA) Will Announce Earnings of -$0.14 Per Share

Wall Street brokerages expect Genocea Biosciences Inc (NASDAQ:GNCA) to post ($0.14) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have issued estimates for Genocea Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.20) and the highest estimate coming in at ($0.10). Genocea Biosciences posted earnings per share of ($0.48) in the same quarter last year, which would indicate a positive year over year growth rate of 70.8%. The business is expected to issue its next earnings results on Thursday, May 3rd.

According to Zacks, analysts expect that Genocea Biosciences will report full year earnings of ($0.55) per share for the current fiscal year, with EPS estimates ranging from ($0.74) to ($0.42). For the next financial year, analysts forecast that the business will report earnings of ($0.61) per share, with EPS estimates ranging from ($0.86) to ($0.45). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover Genocea Biosciences.

How to Become a New Pot Stock Millionaire

Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings data on Friday, February 16th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.40) by $0.03.

A number of brokerages recently issued reports on GNCA. Cantor Fitzgerald set a $5.00 price objective on Genocea Biosciences and gave the company a “buy” rating in a research note on Sunday, March 11th. HC Wainwright began coverage on Genocea Biosciences in a research note on Thursday, March 8th. They issued a “buy” rating and a $5.00 price objective on the stock. Robert W. Baird began coverage on Genocea Biosciences in a research note on Monday, February 12th. They issued an “outperform” rating and a $3.00 price objective on the stock. Needham & Company LLC upgraded Genocea Biosciences from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research note on Tuesday, February 6th. Finally, Zacks Investment Research cut Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Genocea Biosciences currently has a consensus rating of “Buy” and an average price target of $4.41.

Institutional investors and hedge funds have recently made changes to their positions in the company. Millennium Management LLC bought a new stake in shares of Genocea Biosciences during the fourth quarter valued at about $145,000. New York State Common Retirement Fund bought a new stake in shares of Genocea Biosciences during the second quarter valued at about $159,000. California State Teachers Retirement System bought a new stake in shares of Genocea Biosciences during the second quarter valued at about $265,000. Northern Trust Corp increased its position in shares of Genocea Biosciences by 642.9% during the second quarter. Northern Trust Corp now owns 306,597 shares of the biotechnology company’s stock valued at $1,601,000 after buying an additional 265,328 shares during the period. Finally, State Street Corp increased its position in shares of Genocea Biosciences by 1,595.2% during the second quarter. State Street Corp now owns 366,172 shares of the biotechnology company’s stock valued at $1,912,000 after buying an additional 344,572 shares during the period. Hedge funds and other institutional investors own 10.29% of the company’s stock.

Genocea Biosciences stock traded down $0.08 during midday trading on Monday, reaching $0.97. The stock had a trading volume of 1,441,883 shares, compared to its average volume of 1,235,297. Genocea Biosciences has a 12 month low of $0.79 and a 12 month high of $7.29. The stock has a market capitalization of $86.21, a P/E ratio of -0.49 and a beta of 1.20. The company has a debt-to-equity ratio of -1.26, a quick ratio of 0.83 and a current ratio of 0.83.

WARNING: “Brokerages Anticipate Genocea Biosciences Inc (GNCA) Will Announce Earnings of -$0.14 Per Share” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://ledgergazette.com/2018/04/17/brokerages-anticipate-genocea-biosciences-inc-gnca-will-announce-earnings-of-0-14-per-share.html.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Get a free copy of the Zacks research report on Genocea Biosciences (GNCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply